Ami Celeste Knoefler is the Vice President of Investor Relations and Corporate Communications, responsible for managing communications to support and optimize the long-term value of Adagene on behalf of all stakeholders. Ami has more than 25 years of global experience in pharmaceutical, biotech and medical technology communications, including positions at Ascendis Pharma, Jazz Pharmaceuticals, PDL BioPharma, Abgenix and Bristol-Myers Squibb.
Previously, she has led investor and corporate communications for PDL Biopharma and Abgenix, Inc., two antibody platform companies. Her career focus includes Corporate Communications, Product Communications, Patient Advocacy, and Investor Relations. She previously held roles in Global Communications at Ascendis Pharma, where she led corporate marketing, patient advocacy and product communications, and at Jazz Pharmaceuticals, where she led Corporate & Investor Relations activities during a period of transformation and sustained earnings growth.
Ami also founded her own company, Spark BioComm LLC, where she integrated communications and acted as strategic advisor covering investor, corporate, media, and medical communications for small and mid-cap clients.
Ami holds a B.S. from Boston University where she graduated magna cum laude with distinction in International Communications.